gemtuzumab ozogamicin

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
gemtuzumab ozogamicin

GtoPdb Ligand ID: 6775

Synonyms: CDP 771 | CMA 676 | hP67.6-calicheamicin | Mylotarg® | WAY-CMA 676

gemtuzumab ozogamicin is an approved drug (FDA (2000), EMA (2018))

Compound class: Antibody

Comment: This drug is an antibody-drug conjugate (ADC) that targets delivery of the highly cytotoxic ozogamicin (a derivative of calicheamicin γ1) to CD33 +ve myeloid cells [1].

References
1. Bernstein ID. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia, 14 (3): 474-5. [PMID:10720144]
2. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al.. (2012) Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood, 119 (16): 3705-11. [PMID:22378848]

References

1. Bernstein ID. (2000)
Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
Leukemia, 14 (3): 474-5. [PMID:10720144]

2. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al.. (2012)
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
Blood, 119 (16): 3705-11. [PMID:22378848]